E-LIB Suche - Ergebnisse für: Lauri, Birgitta

1

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment w..:

Partanen, Anu ; Waage, Anders ; Peceliunas, Valdas...
Cancers. 16 (2024) 5 - p. 1024 , 2024

2

Idelalisib (PI3Kδ inhibitor) therapy for patients with rela..:

Mattsson, Agnes ; Sylvan, Sandra Eketorp ; Axelsson, Per...
European Journal of Haematology. 111 (2023) 5 - p. 715-721 , 2023

Link: https://doi.org/10.1111/..

3

P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUA..:

Silvennoinen, Raija ; Partanen, Anu ; Waage, Anders...
HemaSphere. 7 (2023) S3 - p. e5534069 , 2023

Link: https://doi.org/10.1097/..

4

P-222: A prospective phase 2 study to assess minimal residu..:

Silvennoinen, Raija ; Waage, Anders ; Peceliunas, Valdas...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S157 , 2022

Link: https://doi.org/10.1016/..

5

Longitudinal minimal residual disease assessment in multipl..:

Schmitz, Alexander ; Brøndum, Rasmus Froberg ; Johnsen, Hans Erik...
BMC Cancer. 22 (2022) 1 - p. , 2022

Link: https://doi.org/10.1186/..

6

Regional differences in treatment and outcome for myeloma p..:

Wålinder, Göran ; Genell, Anna ; Juliusson, Gunnar...
Cancer Reports. 5 (2022) 11 - p. , 2022

Link: https://doi.org/10.1002/..

7

P-184: Regional differences in treatment and outcome for my..:

Wålinder, Göran ; Genell, Anna ; Juliusson, Gunnar...
Clinical Lymphoma Myeloma and Leukemia. 21 (2021) - p. S138 , 2021

Link: https://doi.org/10.1016/..

8

Daratumumab, bortezomib, and dexamethasone in relapsed or r..:

Weisel, Katja ; Spencer, Andrew ; Lentzsch, Suzanne...
Journal of Hematology & Oncology. 13 (2020) 1 - p. , 2020

Link: https://doi.org/10.1186/..

9

Over 10 years relative median survival in MM patients ≤ 65 ..:

Blimark, Cecilie Hveding ; Genell, Anna ; Lund, Johan...
Clinical Lymphoma Myeloma and Leukemia. 19 (2019) 10 - p. e209 , 2019

Link: https://doi.org/10.1016/..

10

Lenalidomide versus lenalidomide + dexamethasone prolonged ..:

Lund, Johan ; Gruber, Astrid ; Lauri, Birgitta...
Cancer Medicine. 7 (2018) 6 - p. 2256-2268 , 2018

Link: https://doi.org/10.1002/..

11

Depth of Response and MRD with Daratumumab Plus Bortezomib ..:

Spencer, Andrew ; Mark, Tomer ; Spicka, Ivan...
Clinical Lymphoma Myeloma and Leukemia. 17 (2017) 1 - p. e85 , 2017

Link: https://doi.org/10.1016/..

12

Pharmacogenetic study of the impact of ABCB1 single-nucleot..:

Jakobsen Falk, Ingrid ; Lund, Johan ; Gréen, Henrik...
Cancer Chemotherapy and Pharmacology. 81 (2017) 1 - p. 183-193 , 2017

Link: https://doi.org/10.1007/..

13

European Post-Approval Safety Study (EU Pass) of Relapsed/R..:

Di Raimondo, Francesco ; Kyriakou, Charalampia ; Schmidt-Hieber, Martin...
Clinical Lymphoma Myeloma and Leukemia. 17 (2017) 1 - p. e62 , 2017

Link: https://doi.org/10.1016/..

14

Improved survival in myeloma patients: starting to close in..:

Liwing, Johan ; Uttervall, Katarina ; Lund, Johan...
British Journal of Haematology. 164 (2013) 5 - p. 684-693 , 2013

Link: https://doi.org/10.1111/..

15

Idelalisib (PI3K delta inhibitor) therapy for patients with..:

Mattsson, Agnes ; Sylvan, Sandra Eketorp ; Axelsson, Per...
European Journal of Haematology, 0902-4441, 2023, 111:5, s. 715-721. , 2023

Link: http://urn.kb.se/resolve..